Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$33.97 USD
-1.15 (-3.27%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $33.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Kymera Therapeutics, Inc. (KYMR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$48.46 | $112.00 | $26.00 | 37.98% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Kymera Therapeutics, Inc. comes to $48.46. The forecasts range from a low of $26.00 to a high of $112.00. The average price target represents an increase of 37.98% from the last closing price of $35.12.
Analyst Price Targets (13)
Broker Rating
Kymera Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, nine are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 60%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 6 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.80 | 1.80 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
2/27/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
2/23/2024 | B. Riley Securities | Kalpit Patel | Hold | Hold |
11/4/2023 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
11/2/2023 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
10/16/2023 | SVB Securities | Thomas J Smith | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 15 |
Average Target Price | $48.46 |
LT Growth Rate | 10.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.72 |